AIDS News and Research

RSS

African summit on treatment of AIDS, tuberculosis and malaria

In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.

8 Apr 2004

Doctors Likelier to Delay Prescribing Antiretroviral Drugs for Women and Minority HIV Patients

A new UCLA study finds that doctors who follow guidelines recommending the delay of antiretroviral therapy for non-adherent HIV patients are likelier to put off that treatment for Latinos, women and poor patients than they do for others. In addition, doctors are slower to prescribe protease inhibitors for African American patients whether or not the physician follows the guidelines.

4 Apr 2004

Compounds that may stop replication of T-cell leukemia virus

Researchers are analyzing several compounds that may inhibit the enzyme that is essential for the reproduction of the Human T-cell Leukemia Virus Type 1 (HTLV-I), which has infected 15 to 20 million people worldwide. The virus causes the fatal adult T-cell leukemia in up to 10 percent of those infected.

1 Apr 2004

First Canadian therapeutic HIV vaccine trial

Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions, including the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) and the Canadian Institutes of Health Research, this project will begin in April.

30 Mar 2004

Almost half of all medicines globally are used irrationally according to WHO

Almost half of all medicines globally are used irrationally. This, say medicines experts at the World Health Organization (WHO), can have severe consequences: adverse drug reactions, drug resistance, protracted illness and even death. In addition, the financial cost incurred by individuals and governments due to irrational use is unnecessary and often extremely high, particularly in developing countries where patients often pay for medicines out of pocket.

29 Mar 2004

IPM takes over Microbicide development to protect against sexual transmission of HIV

International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson. The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect women from infection with HIV. This agreement marks the first collaboration in the microbicide field between a major healthcare company and a public-private partnership such as IPM.

29 Mar 2004

Cryptosporidium parvum parasite could help to develope new therapies for the disease

Cryptosporidium parvum, an insidious, one-celled, waterborne parasite that lodges in the intestines of infected people and animals and for which there is currently no effective treatment, is missing key structures normally found in similar parasites, say researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The results of their genome sequencing project, could help scientists home in on new drug targets that may lead to therapies for the disease.

26 Mar 2004

Joint Research Collaboration to Predict 3-D Protein Structures and Support Drug Discovery

IBM today announced that the University at Buffalo (UB) Center of Excellence in Bioinformatics, The State University of New York, will use IBM technologies and research expertise to study the structure and behavior of human proteins. The outcome of this research could lead to more targeted drugs to treat diseases such as cancer, Alzheimer's, AIDS and multiple sclerosis.

25 Mar 2004

Partnership to improve TB vaccine, Bacillus Calmette-Guérin (BCG)

Crucell N.V.and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates.

25 Mar 2004

£5m for HIV/AIDS trial involving HIV patients in London, Moscow, South Africa and Australia

A joint Oxford University/Imperial College research programme into HIV/AIDS has received £5 million support from the Wellcome Trust to carry out a drug trial involving HIV patients in London, Moscow, South Africa and Australia.

24 Mar 2004

WHO meets in New Delhi on challenge of treating an additional one million patients a year

The number of tuberculosis patients diagnosed and treated under DOTS, the internationally recommended strategy for TB control, is now rising much faster than at any time since DOTS expansion began in 1995, according to a new report by the World Health Organization (WHO). Indeed, the past two years have witnessed accelerated growth in the implementation of DOTS programmes worldwide.

24 Mar 2004

New Cell Sorter Helps Understand Deadly Diseases

Researchers at NC State’s College of Veterinary Medicine have a new state-of-the-art tool, a high-speed cell sorter, that should quicken the pace of their research. The machine sorts or collates cells into groups, allowing scientists to look only at the cells they are working on.

23 Mar 2004

EU gives 32 million Euro for vaccines to stop tuberculosis

The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.

23 Mar 2004

Study shows Kinerase cream aids skin appearance

Valeant Pharmaceuticals announced that it has introduced Kinerase(R) Intensive Eye Cream, based on the successful formula of its Kinerase facial lotion and cream. The new eye cream contains a 25 percent higher concentration of Kinetin, the natural substance in Kinerase products that helps the skin retain moisture and reduces the appearance of fine lines and wrinkles.

22 Mar 2004